https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Bundle of care to drive improvements in palliative and end-of-life care (PEOLC) in an acute tertiary hospital https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53479 Tue 28 Nov 2023 16:00:50 AEDT ]]> Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45592 1c) assessment and notification of diabetes services about patients at intervention hospitals with blood glucose levels of 14 mmol/L or more. Main outcome measure: New diagnoses of diabetes and documented follow‐up plans for patients with admission blood glucose levels of 14 mmol/L or more. Results: Blood glucose was measured in 133 837 patients admitted to hospital from an ED. The numbers of new diabetes diagnoses with documented follow‐up plans for patients with blood glucose levels of 14 mmol/L or more were similar in intervention (83/506 patients, 16%) and control hospitals (73/278, 26%; adjusted odds ratio [aOR], 0.83; 95% CI 0.42–1.7; P = 0.61), as were new diabetes diagnoses with or without plans (intervention, 157/506, 31%; control, 86/278, 31%; aOR, 1.51; 95% CI, 0.83–2.80; P = 0.18). 30‐day re‐admission (31% v 22%; aOR, 1.34; 95% CI, 0.86–2.09; P = 0.21) and post‐hospital mortality rates (24% v 22%; aOR, 1.07; 95% CI, 0.74–1.55; P = 0.72) were also similar for patients in intervention and control hospitals. Conclusion: Glucose and Hb1c screening of patients admitted to hospital from EDs does not alone increase detection of previously unidentified diabetes. Adequate resourcing and effective management pathways for patients with newly detected hyperglycaemia and diabetes are needed. Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12611001007921.]]> Fri 04 Nov 2022 08:55:50 AEDT ]]>